Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported its Q3 2024 financial results and provided a business update. The company is advancing its lead product candidate, PH-762, in a Phase 1b clinical trial following a positive safety recommendation.
November 14, 2024 | 11:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals reported Q3 2024 financial results and is advancing its lead product candidate, PH-762, in clinical trials after receiving a positive safety recommendation.
The advancement of PH-762 in clinical trials following a positive safety recommendation is a significant milestone for Phio Pharmaceuticals. This development could enhance investor confidence and potentially lead to positive short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100